179 related articles for article (PubMed ID: 23700969)
1. Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment.
Malhotra S; Morcillo-Suárez C; Nurtdinov R; Rio J; Sarro E; Moreno M; Castilló J; Navarro A; Montalban X; Comabella M
Eur J Neurol; 2013 Oct; 20(10):1390-7. PubMed ID: 23700969
[TBL] [Abstract][Full Text] [Related]
2. An interdependence between GAPVD1 gene polymorphism, expression level and response to interferon beta in patients with multiple sclerosis.
Khademi B; Khorrami M; Ayromlou H; Rikhtegar R; Moghadam EA; Tahmasebivand M; Mousavi SR; Kheirollahi M; Fakhr F; Alizadeh-Ghodsi M; Emamalizadeh B
J Neuroimmunol; 2021 Apr; 353():577507. PubMed ID: 33548618
[TBL] [Abstract][Full Text] [Related]
3. Sex-specific prediction of interferon beta therapy response in relapsing-remitting multiple sclerosis.
Charbit H; Benis A; Geyshis B; Karussis D; Petrou P; Vaknin-Dembinsky A; Lavon I
J Clin Neurosci; 2015 Jun; 22(6):986-9. PubMed ID: 25882258
[TBL] [Abstract][Full Text] [Related]
4. OAS1: a multiple sclerosis susceptibility gene that influences disease severity.
O'Brien M; Lonergan R; Costelloe L; O'Rourke K; Fletcher JM; Kinsella K; Sweeney C; Antonelli G; Mills KH; O'Farrelly C; Hutchinson M; Tubridy N
Neurology; 2010 Aug; 75(5):411-8. PubMed ID: 20679634
[TBL] [Abstract][Full Text] [Related]
5. Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis.
Vosslamber S; van der Voort LF; van den Elskamp IJ; Heijmans R; Aubin C; Uitdehaag BM; Crusius JB; van der Pouw Kraan TC; Comabella M; Montalban X; Hafler DA; De Jager PL; Killestein J; Polman CH; Verweij CL
Genes Immun; 2011 Sep; 12(6):466-72. PubMed ID: 21471993
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
[TBL] [Abstract][Full Text] [Related]
8. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.
Bustamante MF; Fissolo N; Río J; Espejo C; Costa C; Mansilla MJ; Lizasoain I; Moro MA; Carmen Edo M; Montalban X; Comabella M
Ann Neurol; 2011 Oct; 70(4):634-45. PubMed ID: 22028223
[TBL] [Abstract][Full Text] [Related]
9. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
10. NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis.
Malhotra S; Río J; Urcelay E; Nurtdinov R; Bustamante MF; Fernández O; Oliver B; Zettl U; Brassat D; Killestein J; Lechner-Scott J; Drulovic J; Chan A; Martinelli-Boneschi F; García-Merino A; Montalban X; Comabella M
Brain; 2015 Mar; 138(Pt 3):644-52. PubMed ID: 25586466
[TBL] [Abstract][Full Text] [Related]
11. HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.
Comabella M; Fernández-Arquero M; Río J; Guinea A; Fernández M; Cenit MC; de la Concha EG; Montalban X
J Neuroimmunol; 2009 May; 210(1-2):116-9. PubMed ID: 19349081
[TBL] [Abstract][Full Text] [Related]
12. TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.
Jazireian P; Sasani ST; Assarzadegan F; Azimian M
Mol Biol Rep; 2020 Dec; 47(12):9659-9665. PubMed ID: 33269432
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X
Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: possible pathomechanism of matrix metalloproteinase activation.
Cox MB; Bowden NA; Scott RJ; Lechner-Scott J
Mult Scler; 2013 Sep; 19(10):1268-74. PubMed ID: 23401127
[TBL] [Abstract][Full Text] [Related]
15. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.
Samadzadeh S; Tabibian E; Sabokbar T; Shakoori A; Dehgolan SR; Armaki SA; Aslanbeigi B; Abolfazli R
J Neurol Sci; 2015 May; 352(1-2):37-40. PubMed ID: 25824849
[TBL] [Abstract][Full Text] [Related]
16. Plasma chitotriosidase activity in multiple sclerosis.
Comabella M; Domínguez C; Rio J; Martín-Gallán P; Vilches A; Vilarrasa N; Espejo C; Montalban X
Clin Immunol; 2009 May; 131(2):216-22. PubMed ID: 19176289
[TBL] [Abstract][Full Text] [Related]
17. NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.
Malhotra S; Sorosina M; Río J; Peroni S; Midaglia L; Villar LM; Álvarez-Cermeño JC; Schroeder I; Esposito F; Clarelli F; Zettl UK; Lechner-Scott J; Spataro N; Navarro A; Comi G; Montalban X; Martinelli-Boneschi F; Comabella M
Mult Scler; 2018 Oct; 24(11):1507-1510. PubMed ID: 29117789
[TBL] [Abstract][Full Text] [Related]
18. Modulating effects of WT1 on interferon-β-vitamin D association in MS.
Lin R; Taylor BV; Charlesworth J; van der Mei I; Blizzard L; Stewart N; Ponsonby AL; Dwyer T; Pittas F; Simpson S
Acta Neurol Scand; 2015 Apr; 131(4):231-9. PubMed ID: 25312909
[TBL] [Abstract][Full Text] [Related]
19. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients.
Weinstock-Guttman B; Hong J; Santos R; Tamaño-Blanco M; Badgett D; Patrick K; Baier M; Feichter J; Gallagher E; Garg N; Ramanathan M
Mult Scler; 2006 Oct; 12(5):541-50. PubMed ID: 17086898
[TBL] [Abstract][Full Text] [Related]
20. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
